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The Authors Reply: We thank Pliquett et al.1 for their interest
in our article.2 Contrary to what is suggested in their title, we
did not investigate hemodialysis and peritoneal dialysis (PD)
outcomes in patients with chronic heart disease, but we com-
pared survival by dialysis modality in incident end-stage renal
disease patients with congestive heart failure (CHF).2
As they point out,1 our study is observational by nature.
Limitations of such studies, including CHF diagnosis, New York
Heart Association (NYHA) class diagnosis, and nonavailability of
surrogates of CHF, were discussed in the paper.2 Unfortunately,
the cause of CHF is not available in the REIN Registry.
Reliability of CHF diagnosis is based on quality control
procedures and on our validation study.2 Echocardiographic
or biological markers could not be surrogates of CHF in the
absence of validated criteria for diagnosis.3 The use of data
after dialysis initiation, as hydration level, would have led to a
selection bias because they depend on dialysis modality.4
The REIN Registry does not differentiate NYHA stages III
and IV. However, we can hypothesize that the majority of patients
with glomerular ﬁltration rate X15ml/min per 1.73m2 had
NYHA IV CHF. In this group, PD mortality remained higher.2
Epidemiological studies aim to generate hypotheses and
improve previous reports. Only a randomized trial could ensure
the veracity of survival comparison by dialysis modality.
Waiting for further evidence, dialysis modality choice
should take into account quality of life, patient’s preferences,
and economic data. It seems reasonable to advise nephrologists
to pay particular attention to CHF patients on PD.
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Red blood cell life span and
‘erythropoietin resistance’
To the Editor: We read with interest Bamgbola’s review on
erythropoietin (EPO) resistance in a recent issue of the Journal.1
Although the author presents a wide range of mechanisms
and conditions associated with EPO resistance (including
‘accelerated turnover rate of red cells’), the integral role of red
blood cell (RBC) life span deserved more explicit elaboration,
in our opinion. The response to EPO, meaning the hemoglo-
bin (Hgb) concentration achieved with a certain EPO regimen,
is really a continuum rather than a binary outcome, and RBC
life span (RBCLS) is a basic component of the process.2,3
Reduction in RBCLS will necessarily entail a reduction in Hgb
unless compensated for by increased RBC production rate
(in dialysis patients primarily mediated by EPO and iron
therapy). When RBC production cannot increase materially,
regardless of increases in EPO dose, a short RBCLS becomes
the limiting factor in Hgb increase, giving the impression of
resistance to EPO.
We have determined RBCLS repeatedly in 44 hemodialysis
(HD) patients by carbon monoxide measurements4 and saw
an average baseline RBCLS of 70±23 days, which is in keeping
with literature data. It is noteworthy that only one of these
patients met the criteria of EPO resistance cited by Bamgbola,
illustrating how rarely this deﬁnition is met. During this
period, RBCLS was measured twice in this patient (spaced one
month apart) and was found to be 35.9 days and 39.4 days,
respectively (Figure 1). Diagnostic workup according to the
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Figure 1 |Time course of epoetin alfa dose, hemoglobin
concentration, and red blood cell life span (RBCLS) in a
patient with ‘EPO resistance’. EPO, erythropoietin.
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